Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions.

PubWeight™: 1.96‹?› | Rank: Top 2%

🔗 View Article (PMC 188920)

Published in J Virol on April 01, 1995

Authors

A Billich1, F Hammerschmid, P Peichl, R Wenger, G Zenke, V Quesniaux, B Rosenwirth

Author Affiliations

1: Sandoz Forschungsinstitut GmbH, Vienna, Austria.

Articles citing this

Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol (1996) 4.15

Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol (2005) 2.54

N-Terminal extension of human immunodeficiency virus capsid protein converts the in vitro assembly phenotype from tubular to spherical particles. J Virol (1998) 2.49

Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. J Virol (1996) 2.49

The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811. J Virol (1996) 2.43

Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins. J Virol (1996) 2.07

Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol (2005) 1.82

NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob Agents Chemother (2006) 1.69

Cyclophilin catalyzes protein folding in yeast mitochondria. Proc Natl Acad Sci U S A (1995) 1.60

Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother (2008) 1.46

SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother (2009) 1.35

Cells with high cyclophilin A content support replication of human immunodeficiency virus type 1 Gag mutants with decreased ability to incorporate cyclophilin A. J Virol (1998) 1.29

The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. J Bioenerg Biomembr (2004) 1.27

Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions. J Virol (1997) 1.25

Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes. Proc Natl Acad Sci U S A (1998) 1.24

Mechanistic independence of Nef and cyclophilin A enhancement of human immunodeficiency virus type 1 infectivity. Virology (1998) 1.17

The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother (2002) 1.16

Analysis of human cell heterokaryons demonstrates that target cell restriction of cyclosporine-resistant human immunodeficiency virus type 1 mutants is genetically dominant. J Virol (2007) 1.13

Curing a viral infection by targeting the host: the example of cyclophilin inhibitors. Antiviral Res (2013) 1.10

Specifically targeted antiviral therapy for hepatitis C virus. World J Gastroenterol (2007) 1.10

Cyclophilin a plays distinct roles in human immunodeficiency virus type 1 entry and postentry events, as revealed by spinoculation. J Virol (2002) 1.05

The TB Structural Genomics Consortium: a decade of progress. Tuberculosis (Edinb) (2011) 1.03

Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein. Antimicrob Agents Chemother (2009) 1.03

Cloning and biochemical characterization of the cyclophilin homologues from the free-living nematode Caenorhabditis elegans. Biochem J (1996) 1.00

Cyclophilin A-induced alterations of human immunodeficiency virus type 1 CA protein in vitro. J Virol (1997) 0.99

A cell-impermeable cyclosporine A derivative reduces pathology in a mouse model of allergic lung inflammation. J Immunol (2010) 0.96

Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. J Virol (2010) 0.95

Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A. Nucleic Acids Res (2004) 0.95

Secreted cyclophilin A, a peptidylprolyl cis-trans isomerase, mediates matrix assembly of hensin, a protein implicated in epithelial differentiation. J Biol Chem (2008) 0.94

Cyclosporine inhibits mouse cytomegalovirus infection via a cyclophilin-dependent pathway specifically in neural stem/progenitor cells. J Virol (2007) 0.92

Chimeric human immunodeficiency virus type 1 (HIV-1) virions containing HIV-2 or simian immunodeficiency virus Nef are resistant to cyclosporine treatment. J Virol (2004) 0.90

trans-Complementation rescue of cyclophilin A-deficient viruses reveals that the requirement for cyclophilin A in human immunodeficiency virus type 1 replication is independent of its isomerase activity. J Virol (2002) 0.90

Blocking cyclophilins in the chronic phase of asthma reduces the persistence of leukocytes and disease reactivation. Am J Respir Cell Mol Biol (2011) 0.87

Peptidyl prolyl cis-trans isomerase activity of cyclophilin A in functional homo-oligomeric receptor expression. Proc Natl Acad Sci U S A (1997) 0.86

New therapeutic approaches to hepatitis C virus. J Gastroenterol (2009) 0.86

Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. Infect Dis Obstet Gynecol (1999) 0.84

Knockdown of the cellular protein LRPPRC attenuates HIV-1 infection. PLoS One (2012) 0.83

Suppression of feline coronavirus replication in vitro by cyclosporin A. Vet Res (2012) 0.81

The intriguing cyclophilin A-HIV-1 Vpr interaction: prolyl cis/trans isomerisation catalysis and specific binding. BMC Struct Biol (2010) 0.81

Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms. Viruses (2013) 0.81

The host-pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains. BMC Struct Biol (2011) 0.81

Chimeric human immunodeficiency virus type 1 virions that contain the simian immunodeficiency virus nef gene are cyclosporin A resistant. J Virol (2005) 0.81

The role of immunophilins in viral infection. Biochim Biophys Acta (2014) 0.80

Nuclear Envelope Protein SUN2 Promotes Cyclophilin-A-Dependent Steps of HIV Replication. Cell Rep (2016) 0.80

Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics. Clin Diagn Lab Immunol (1998) 0.79

Complex Interplay between HIV-1 Capsid and MX2-Independent Alpha Interferon-Induced Antiviral Factors. J Virol (2016) 0.78

Identification of HIV inhibitors guided by free energy perturbation calculations. Curr Pharm Des (2012) 0.77

Contribution of glutamine residues in the helix 4-5 loop to capsid-capsid interactions in simian immunodeficiency virus of macaques. J Virol (2014) 0.76

Delaying reverse transcription does not increase sensitivity of HIV-1 to human TRIM5α. PLoS One (2013) 0.76

Cycloheximide promotes paraptosis induced by inhibition of cyclophilins in glioblastoma multiforme. Cell Death Dis (2017) 0.75

Suppression of coronavirus replication by cyclophilin inhibitors. Viruses (2013) 0.75

Proteomic profiling of SupT1 cells reveal modulation of host proteins by HIV-1 Nef variants. PLoS One (2015) 0.75

Articles cited by this

Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol (1990) 61.47

Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32

HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell (1991) 15.76

HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J (1990) 9.34

Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science (1985) 9.27

Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature (1981) 9.25

Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science (1984) 8.01

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods (1988) 7.74

Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell (1993) 7.34

Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci U S A (1992) 6.85

Functional association of cyclophilin A with HIV-1 virions. Nature (1994) 6.82

Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11

Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science (1986) 5.86

Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85

Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med (1992) 5.29

Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol (1993) 3.01

Binding of human immunodeficiency virus type 1 (HIV-1) RNA to recombinant HIV-1 gag polyprotein. J Virol (1991) 3.00

Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature (1987) 2.86

[Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides]. Biomed Biochim Acta (1984) 2.80

Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother (1994) 2.26

Catalysis of protein folding by prolyl isomerase. Nature (1987) 2.21

Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites. Drug Metab Dispos (1984) 2.01

Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob Agents Chemother (1994) 1.98

Transcomplementation of VIF- HIV-1 mutants in CEM cells suggests that VIF affects late steps of the viral life cycle. Virology (1993) 1.74

Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction. J Biol Chem (1992) 1.62

An AIDS-related cytotoxic autoantibody reacts with a specific antigen on stimulated CD4+ T cells. Nature (1987) 1.57

The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1. Blood (1988) 1.56

Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication. J Virol (1995) 1.44

Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity. Eur J Immunol (1987) 1.21

Characterization of an HIV-2-related virus with a smaller sized extracellular envelope glycoprotein. Virology (1989) 1.20

Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol (1989) 1.16

An idiotypic network model of AIDS immunopathogenesis. Proc Natl Acad Sci U S A (1991) 1.12

AIDS and related syndromes as a viral-induced autoimmune disease of the immune system: an anti-MHC II disorder. Therapeutic implications. AIDS Res (1986) 1.08

The relevance of HIV env/CD4 interactions to the pathogenesis of acquired immune deficiency syndrome. J Acquir Immune Defic Syndr (1989) 1.07

Purification, assay and kinetic features of HIV-1 proteinase. Biol Chem Hoppe Seyler (1990) 1.02

Thermal stability and folding of type IV procollagen and effect of peptidyl-prolyl cis-trans-isomerase on the folding of the triple helix. J Biol Chem (1989) 0.98

Specific cross-linking of the proline isomerase cyclophilin to a non-proline-containing peptide. Mol Biol Cell (1993) 0.94

Cis-trans isomerization is rate-determining in the reactivation of denatured human carbonic anhydrase II as evidenced by proline isomerase. FEBS Lett (1992) 0.90

Molecular mechanisms of immunosuppression. J Autoimmun (1992) 0.88

HIV. Cyclophilins unfold the Gag? Nature (1993) 0.88

Measurement of HIV-1 reverse transcriptase by a nonradioactive assay system. Ann N Y Acad Sci (1992) 0.83

Inhibitors of HIV-1 proteinase containing 2-heterosubstituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity. J Med Chem (1994) 0.81

Cyclosporin binding proteins. Identification, distribution, function and relation to FK binding proteins. Biochem Pharmacol (1993) 0.79

Simian T-lymphotropic viruses and related human viruses. Vet Microbiol (1988) 0.78

Comparison of the properties of the CsA analogs monoacetyl CyC (o-acetyl-threonine2 cyclosporin) and methyl-alanyl CsA (N-methyl-L-alanyl6 cyclosporin); monoacetyl cyclosporin is immunosuppressive without binding to cyclophilin. Clin Exp Immunol (1992) 0.78

Articles by these authors

Functional association of cyclophilin A with HIV-1 virions. Nature (1994) 6.82

CagA/cytotoxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cell lines. J Clin Pathol (1994) 3.48

Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol (1993) 3.22

Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. J Clin Pathol (1994) 3.16

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation (1997) 2.80

Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activation. J Cell Biol (1993) 2.64

Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother (1994) 2.26

Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob Agents Chemother (1994) 1.98

A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol (1998) 1.79

Incomplete particles of adenovirus. II. Kinetics of formation and polypeptide composition of adenovirus type 2. Virology (1974) 1.74

Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob Agents Chemother (1996) 1.51

Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication. J Virol (1995) 1.44

Insertion mutations in the control region of the Gal operon of E. coli. I. Biological characterization of the mutations. Mol Gen Genet (1972) 1.44

Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother (2000) 1.42

Tryptic fingerprint analysis of adenovirus types 2, 5 and 12 DNA-Binding proteins. Virology (1976) 1.35

Adenovirus-infected, cell-specific, DNA-binding proteins. Cold Spring Harb Symp Quant Biol (1975) 1.34

Interleukin-3 is a differentiation factor for human basophils. Blood (1989) 1.34

Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis. J Exp Med (1997) 1.31

P-glycoprotein-mediated secretion of a fluorescent cyclosporin analogue by teleost renal proximal tubules. Am J Physiol (1995) 1.30

Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum. J Clin Invest (1992) 1.25

Early processes of echovirus 12-infection: elution, penetration, and uncoating under the influence of rhodanine. Virology (1979) 1.24

Molecular cloning and sequence determination of the genomic regions encoding protease and genome-linked protein of three picornaviruses. J Virol (1986) 1.23

The relationship between group C adenovirus tumor antigen and the adenovirus single-strand DNA-binding protein. Cell (1976) 1.19

Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest (1998) 1.19

Isolation and characterization of adenovirus type 12 DNA binding proteins. Virology (1975) 1.18

Purification and partial characterization of poliovirus protease 2A by means of a functional assay. J Virol (1988) 1.13

NLRP3 inflammasome is required in murine asthma in the absence of aluminum adjuvant. Allergy (2011) 1.13

SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation (1997) 1.06

Purification, assay and kinetic features of HIV-1 proteinase. Biol Chem Hoppe Seyler (1990) 1.02

2'-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity. J Med Chem (1987) 0.99

New insights into mechanisms of atrial fibrillation. Physiol Res (2009) 0.98

A comparison of cyclosporine binding by cyclophilin and calmodulin and the identification of a novel 45 KD cyclosporine-binding phosphoprotein in Jurkat cells. Transplantation (1988) 0.97

Studies on protein kinases involved in regulation of nucleocytoplasmic mRNA transport. Biochem J (1988) 0.96

Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta. Virology (1997) 0.96

In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages. J Leukoc Biol (1994) 0.96

A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol (1999) 0.95

IgG isotype distribution of local and systemic immune responses induced by influenza virus infection. Eur J Immunol (1994) 0.95

Immunostimulatory, but not antiendotoxin, activity of lipid X is due to small amounts of contaminating N,O-acylated disaccharide-1-phosphate: in vitro and in vivo reevaluation of the biological activity of synthetic lipid X. Infect Immun (1991) 0.95

Modulation of nuclear matrix-associated 2',5'-oligoadenylate metabolism and ribonuclease L activity in H9 cells by human immunodeficiency virus. J Biol Chem (1989) 0.95

Plasmodium vivax: in vitro antiparasitic effect of cyclosporins. Exp Parasitol (1996) 0.94

Binding of Tat protein to TAR region of human immunodeficiency virus type 1 blocks TAR-mediated activation of (2'-5')oligoadenylate synthetase. AIDS Res Hum Retroviruses (1990) 0.93

The interleukin-17 gene of herpesvirus saimiri. J Virol (1998) 0.92

High-level expression of a human immunoglobulin gamma 1 transgene depends on switch region sequences. Eur J Immunol (1992) 0.92

DNA copy number gains in head and neck squamous cell carcinoma. Oncogene (2006) 0.92

Cyclosporine and its analogue SDZ IMM 125 mediate very similar effects on T-cell activation--a comparative analysis in vitro. Transplant Proc (1992) 0.91

Novel thiosemicarbazones derived from formyl- and acyldiazines: synthesis, effects on cell proliferation, and synergism with antiviral agents. J Med Chem (1992) 0.91

Molecular mechanisms of immunosuppression by cyclosporins. Ann N Y Acad Sci (1993) 0.91

Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. I. Taxonomy, fermentation, isolation and biological activity. J Antibiot (Tokyo) (1999) 0.90

HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Immunol Lett (1999) 0.90

Biochemistry and pathogenicity of echovirus 9. I. Characterization of the virus particles of strains Barty and Hill. Virology (1982) 0.90

Pharmacology of cyclosporine (sandimmune). I. Introduction. Pharmacol Rev (1990) 0.89

Herpesvirus saimiri vFLIP provides an antiapoptotic function but is not essential for viral replication, transformation, or pathogenicity. J Virol (2000) 0.88

Structure-activity relationship study of human interleukin-3: role of the C-terminal region for biological activity. EMBO J (1991) 0.88

Molecular mechanisms of immunosuppression. J Autoimmun (1992) 0.88

Autocrine or paracrine transforming growth factor-beta modulates the phenotype of chick embryo sternal chondrocytes in serum-free agarose culture. J Biol Chem (1993) 0.88

Structural and functional analysis of an rRNA operon and its flanking tRNA genes from Zea mays chloroplasts. Nucleic Acids Symp Ser (1982) 0.86

Characterization of an adenovirus early protein required for viral DNA replication: a single strand specific DNA binding proteins. Mol Cell Biochem (1976) 0.86

Contribution of donor-specific antibodies to acute allograft rejection: evidence from B cell-deficient mice. Transplantation (1998) 0.86

The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells. J Gen Virol (1997) 0.86

5-(Haloalkyl)-2'-deoxyuridines: a novel type of potent antiviral nucleoside analogue. J Med Chem (1985) 0.85

Mapping the epitopes of neutralizing anti-human IL-3 monoclonal antibodies. Implications for structure-activity relationship. J Immunol (1991) 0.85

Malaria toxins from P. chabaudi chabaudi AS and P. berghei ANKA cause dyserythropoiesis in C57BL/6 mice. Parasitology (1997) 0.85

Alteration of nuclear (2'-5')oligoriboadenylate synthetase and nuclease activities preceding replication of human immunodeficiency virus in H9 cells. Biol Chem Hoppe Seyler (1988) 0.85

Cyclosporins. Structure-activity relationships. Ann N Y Acad Sci (1993) 0.85

Biochemical markers in menopausal women. Scand J Clin Lab Invest Suppl (1997) 0.84

Cytochalasin B selectively releases ovalbumin mRNA precursors but not the mature ovalbumin mRNA from hen oviduct nuclear matrix. Eur J Biochem (1987) 0.84

T-cell lymphoma caused by herpesvirus saimiri C488 independently of ie14/vsag, a viral gene with superantigen homology. J Virol (1998) 0.84

Independence of herpesvirus-induced T cell lymphoma from viral cyclin D homologue. J Exp Med (2001) 0.84

Association of Tat protein and viral mRNA with nuclear matrix from HIV-1-infected H9 cells. Biochim Biophys Acta (1989) 0.84

Measurement of HIV-1 reverse transcriptase by a nonradioactive assay system. Ann N Y Acad Sci (1992) 0.83

The origin of cynomolgus monkey affects the outcome of kidney allografts under Neoral immunosuppression. Transplant Proc (2002) 0.83

Cyclosporine and analogues: structural requirements for immunosuppressive activity. Transplant Proc (1986) 0.83

Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives. Br J Cancer (1989) 0.83

Identification of cyclophilin as the erythrocyte ciclosporin-binding protein. Biochim Biophys Acta (1988) 0.83

Synthesis and antiviral activity of thiosemicarbazone derivatives of pyridazinecarbaldehydes and alkyl pyridazinyl ketones. Arzneimittelforschung (1989) 0.82

Histamine plays an essential regulatory role in lung inflammation and protective immunity in the acute phase of Mycobacterium tuberculosis infection. Infect Immun (2009) 0.82

Potential of monoclonal antibodies to improve therapeutic monitoring of cyclosporine. Clin Chem (1987) 0.82

ABO-incompatible bone marrow transplantation: in vivo adsorption, an old forgotten method. Transplant Proc (1987) 0.82

Phage display as a rapid gene expression system: production of bioactive cytokine-phage and generation of neutralizing monoclonal antibodies. J Immunol Methods (1993) 0.81

Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. Ren Physiol Biochem (1995) 0.81

Selective in vitro and in vivo activities of 5-(2-haloalkyl)pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus. Antimicrob Agents Chemother (1985) 0.81

Inhibitors of HIV-1 proteinase containing 2-heterosubstituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity. J Med Chem (1994) 0.81

Interaction of cyclosporin A with an Fab fragment or cyclophilin. Affinity measurements and time-dependent changes in binding. FEBS Lett (1993) 0.81

[Successfully operated hemangioblastoma of the right atrium]. Z Kreislaufforsch (1972) 0.81

Effect of nonviable preparations from human immunodeficiency virus type 1 on nuclear matrix-associated DNA polymerase alpha and DNA topoisomerase II activities. J Acquir Immune Defic Syndr (1990) 0.81

Structure-activity relationship study of human interleukin-3. Identification of residues required for biological activity by site-directed mutagenesis. J Biol Chem (1991) 0.80

Differential effect of insulin and epidermal growth factor on the mRNA translocation system and transport of specific poly(A+) mRNA and poly(A-) mRNA in isolated nuclei. Biochemistry (1990) 0.80

The continuing search for new immunomodulators. Transplant Proc (1992) 0.80

Interactions of HIV-1 proteins with human T-cell cyclophilin A. Ann N Y Acad Sci (1996) 0.80

Regulation and targeting of T-cell immune responses by IgE and IgG antibodies. Immunology (1995) 0.80